LAUSR

Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, Mcmillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4. CAS Article Google Scholar Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. CAS Article Google Scholar MHRA. https://mhraproducts4853.blob.core.windows.net/docs/5dfe0ce949110e10fe7ff2775a454e38ae2395c7. Accessed February 2019. GRAY RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1998;16:1141–54. Article Google Scholar GRAY JPFARJ. A proportional Hazards Model for Subdistribution of a Competing Risk. J Am Stat Assoc. 1997;94:496–509. Google Scholar Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, et al. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant. 2016;51:1397–9. CAS Article Google Scholar Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus. 2013;2:489. Article Google Scholar Download references The authors acknowledge the contribution of data from each centre; St George’s Hospital (M Koh, A Drake), Cardiff (K Wilson, D Davies), Christie Hospital Manchester (A Bloor, A Sjursen) Leeds (M Gilleece, R Goodall, C Mountain, H Moss) Southampton (K Orchard, R Lown) Nottingham (N Russell, E Cox) St Bartholomews (J Gribben, D Anderson) Royal Marsden (M Potter, E Nicholson) Edinburgh (A Broom) Newcastle (M Collin, L Duncan) Leicester (M Martin, R Lewin) Brimingham Heartlands (M Nikolousis, M Sharkey) Coventry (F Jones, W Harris-Bailey) Ireland (A Hayat, N Mannion) Derriford/Plymouth (H Hunter, A Whitnall) Poole (F Jack, S Pope) North Staffordshire (S Pillai, K Yarwood) Taunton and Somerset (S Bolam, M Ewings) Cheltenham (S Chown, C Carter) Bournemouth (R Hall, J Davies) Manchester (E Tholouli, E Marchan) Swindon (N Blessing, L Ishmael-Walrond) Dudley (S Fernandes) Bath (C Knetchli, T Peters). Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK Philippa Kelsey, John A. Snowden & Nick Morley British Society of Blood and Marrow Transplantation, London, UK Rachel Pearce, Julia Perry, Keiren Kirkland & Ruth Paul University College London Hospitals NHS Foundation Trust, London, UK Jonathan Lambert Oxford University Hospitals NHS Foundation Trust, Oxford, UK Andy Peniket University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK Ram Malladi You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar You can also search for this author in PubMed Google Scholar The Authors contributions were as follows: PK- Wrote the paper. RP- Study statistician. JP- Study co-ordinator. KK- Data manager. RP- Oversaw data collection. JAS- Co-investigator. JL- Contribution of significant patient numbers. NM- Study Chair. Correspondence to Philippa Kelsey. The authors declare that they have no conflict of interest. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reprints and Permissions Kelsey, P., Pearce, R., Perry, J. et al. Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma—a retrospective study from the BSBMT (BEAM versus LEAM). Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01071-2 Download citation Received: 10 March 2020 Revised: 08 September 2020 Accepted: 21 September 2020 Published: 29 September 2020 DOI: https://doi.org/10.1038/s41409-020-01071-2